Transcript

Crafting a plan: Jamie's story with bipolar II depression

(DESCRIPTION)

Video begins with white background and text in the center of the screen, and the ITCI logo centered at the bottom of the screen.

(ON SCREEN TEXT)

Jamie's story with bipolar II depression

[ITCI logo]

The on screen text fades off screen and new text fades in. The ITCI logo remains in place.

(ON SCREEN TEXT)

The patient and healthcare provider in this video are sharing their individual experiences. They have been compensated for their time. This resource is brought to you by Intra-Cellular Therapies.

(DESCRIPTION)

Screen cuts to a mountain view. Jamie slowly emerges from the bottom left corner, walking forward.

(Jamie)

I started feeling depression symptoms when I was a young kid. I did feel down a lot. I don't feel I got the support I needed.

(DESCRIPTION)

Camera cuts to Jamie talking to the camera with on screen text in the bottom left.

(ON SCREEN TEXT)

Jamie

Patient Advocate with Bipolar II Depression

(Jamie)

Shortly after I got married, my depression symptoms felt as if they were worsening. When it was causing struggles in our marriage, I personally recognized I need to finally get the help I need.

(DESCRIPTION)

On screen text disappears and camera cuts to Jamie walking through a forest.

(Jamie)

And at that point, I was diagnosed with major depressive disorder. It was quite a good chunk of time of, you know, 11 to 12 years of—of trying different antidepressants. I honestly felt depression worsening at times.

Then, when I was in my early 30s, my symptoms became severe. I started becoming dysfunctional at work. I didn't want to craft anymore, so I shut off my craft business and I didn't craft for a long time, and it was kind of saddening for me. At home, my kids were kind of like, “What is going on with you, Mom?” My husband and I would fight more often.

(DESCRIPTION)

Camera cuts to Jamie, writing on a notebook in the forest.

(Jamie)

I would feel these urges to randomly do things that I normally wouldn't. It was just this sudden burst of, “I need to go, I have to do this, and I have to go do it now.” I realized my uncontrollable moods were hurting my relationship with my family, so I decided to open up to my healthcare provider.

When I started bringing up my worsening symptoms, she diagnosed me with bipolar II depression. It made sense when I looked back at the symptoms I experienced for most of my life. One of the first medications she brought up to me was CAPLYTA (lumateperone).

(DESCRIPTION)

Camera cuts to Amy, speaking to the camera. On screen text appears in the bottom left corner and then disappears.

(ON SCREEN TEXT)

Amy Belnap

APRN, PMHNP-BC

(Amy)

CAPLYTA is an FDA-approved prescription medication used to treat depressive episodes associated with bipolar I or bipolar II disorder in adults.

Camera cuts to Jamie, working on her crafts.

(Amy)

CAPLYTA is proven to reduce depressive symptoms from bipolar I and II, and it has a well-established safety profile. Its also one of a few medications approved to treat bipolar II depression, which is what Jamie has.

Bipolar I and II have a similar patient population size, yet many people don't know the difference between them. In Jamie's case, having bipolar II depression means she tends to experience longer depressive episodes that can be more severe than with bipolar I, while not experiencing debilitating bouts of mania or needing to go to the hospital.

This can make bipolar II hard to diagnose, as it can frequently be confused with major depressive disorder. Antidepressant medications may worsen bipolar symptoms, so a proper diagnosis is critical.

(ON SCREEN TEXT)

3 in 4 patients with bipolar disorder are misdiagnosed, most often with major depressive disorder (MDD).

(Amy)

The ability to differentiate bipolar I and bipolar II disorder really hinges on the identification of manic and hypomanic symptoms.

I've found that most of my patients who take CAPLYTA tolerate it well. Many of them are worried about side effects. I let them know that in CAPLYTA clinical trials, weight gain and movement disorders were not common. And the dosing is convenient—it's one pill, taken just once a day with or without food.

(ON SCREEN TEXT)

High cholesterol and weight gain may occur, as can high blood sugar, which may be fatal. Monitoring is recommended.

(Amy)

I thought CAPLYTA could really help Jamie find relief from her symptoms. Of course, every patient's experience with CAPLYTA will be different.

(ON SCREEN TEXT)

Call your doctor about new or serious side effects like sudden mood changes, behaviors, or suicidal thoughts right away. Antidepressants may increase these risks.

(Amy)

I tell my patients who take CAPLYTA to call me right away if they experience potential side effects like sudden mood changes, behaviors, or suicidal thoughts. I also tell them to talk to me about any concerns or questions they might have about treatment.

(ON SCREEN TEXT)

Please see Important Safety Information at the end of this video.

(Amy)

I make sure they review the Important Safety Information for CAPLYTA, which is included at the end of this video.

(ON SCREEN TEXT)

Elderly dementia patients have increased risk of death or stroke. CAPLYTA is not approved for dementia-related psychosis.

(Amy)

But CAPLYTA isn't for everyone. It's not approved for elderly patients with dementia-related psychosis, because it can increase the risk of death or stroke.

Camera cuts to Jamie.

(Jamie)

Amy and I had a really good conversation about CAPLYTA. I also liked how there was no titration needed. I was on the effective dose from the start.

The camera cuts to Jamie and her children cooking together in the kitchen.

(ON SCREEN TEXT)

Report fever, confusion, stiff muscles, which may be life-threatening, or uncontrolled muscle movements, which may be permanent.

(Amy)

I let my patients know they may see some improvement as early as the first week, with additional relief over the course of six weeks. But again, everyone's experience might be different.

I tell my patients to watch for possible side effects, and let me know if they have fever, confusion, or stiff muscles, which may be life threatening, or uncontrolled muscle movements which may be permanent.

(ON SCREEN TEXT)

Common side effects are sleepiness, dizziness, nausea, and dry mouth. These aren't all the side effects.

(Jamie)

Before I started CAPLYTA, I told my healthcare provider about all the medical conditions I had and medications I was taking. We went over the potential benefits and risks of treatment, including the most common side effects which are sleepiness, dizziness, nausea, and dry mouth.

Camera cuts to Jamie, speaking to the camera. On screen text appears in the bottom left corner and then disappears.

(ON SCREEN TEXT)

Individual results may vary. Talk to your doctor to see if CAPLYTA might be right for you.

(Jamie)

After taking CAPLYTA for a few weeks, I noticed some improvements in my bipolar depression symptoms.

The camera cuts to Jamie and her children cooking together in the kitchen.

(Amy)

I'm happy with the progress Jamie is making on CAPLYTA. It's made such a difference in her bipolar depression symptoms. I'm glad Jamie trusted me and opened up to me about her challenges with bipolar II. That's what has helped get to the correct diagnosis, and a treatment plan that she's on now.

(Jamie)

I'm happy with the progress I've made on CAPLYTA. I still see Amy regularly and I still seek therapy on a routine basis.

It's a relief to know what was causing my symptoms for most of my life. Having relief from my bipolar depression means I'm able to focus on other parts of my life, like my work. I love spending time with my family.

To anybody out there who is currently seeking help, go talk to somebody, because it's so worth getting the help you need.

(DESCRIPTION)

Screen goes white. Previous on screen text disappears and Important Safety Information appears on screen. The CAPLYTA logo remains in the bottom right corner and the ITCI logo is in the top right corner. Important Safety Information begins scrolling as it's read on voiceover.

(ON SCREEN TEXT)

[ITCI logo]

[CAPLYTA logo] FOR BIPOLAR I & II DEPRESSION

Important Safety Information

Medicines like CAPLYTA can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). CAPLYTA is not approved for treating people with dementia-related psychosis.

CAPLYTA and antidepressant medicines may increase suicidal thoughts and actions in some children, adolescents, and young adults especially within the first few months of treatment or when the dose is changed. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Patients and their families or caregivers should watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when CAPLYTA or an antidepressant medicine is started or when the dose is changed. Report any change in these symptoms to your healthcare provider immediately.

Do not take CAPLYTA if you are allergic to any of its ingredients. Get emergency medical help if you are having an allergic reaction (e.g., rash, itching, hives, swelling of the tongue, lip, face, or throat).

CAPLYTA may cause serious side effects, including:

Stroke (cerebrovascular problems) in elderly people with dementia‑related psychosis that can lead to death.
Neuroleptic malignant syndrome (NMS): high fever, confusion, changes in your breathing, heart rate, and blood pressure, stiff muscles, and increased sweating; these may be symptoms of a rare but potentially fatal condition. Contact your healthcare provider or go to the emergency room if you experience signs and symptoms of NMS.
Uncontrolled body movements (tardive dyskinesia, TD) in your face, tongue, or other body parts. TD may not go away, even if you stop taking CAPLYTA. It may also occur after you stop taking CAPLYTA.
Problems with your metabolism including high blood sugar, diabetes, increased fat (cholesterol and triglyceride) levels in your blood and weight gain. Your healthcare provider should check your blood sugar, fat levels and weight before you start and during your treatment with CAPLYTA. Extremely high blood sugar levels can lead to coma or death. Call your healthcare provider if you have any of the following symptoms of high blood sugar: feeling very thirsty, hungry, sick to your stomach, needing to urinate more than usual, weak/tired, or confused, or your breath smells fruity.
Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with CAPLYTA.
Decreased blood pressure (orthostatic hypotension). You may feel lightheaded, dizzy, or faint when you rise too quickly from a sitting or lying position.
Falls. CAPLYTA may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause broken bones or other injuries.
Seizures (convulsions).
Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities. Until you know how CAPLYTA affects you, do not drive, operate heavy machinery, or do other dangerous activities.
Problems controlling your body temperature so that you feel too warm. Avoid getting overheated or dehydrated while taking CAPLYTA.
Difficulty swallowing that can cause food or liquid to get into the lungs.

The most common side effects of CAPLYTA include sleepiness, dizziness, nausea, and dry mouth.

These are not all the possible side effects of CAPLYTA. Tell your healthcare provider if you have or have had heart problems or a stroke, high or low blood pressure, diabetes, or high blood sugar, problems with cholesterol, have or have had seizures (convulsions), kidney or liver problems, or a low white blood cell count. CAPLYTA may cause fertility problems in females and males. You should notify your healthcare provider if you become pregnant or intend to become pregnant while taking CAPLYTA. CAPLYTA may cause abnormal involuntary movements and/or withdrawal symptoms in newborn babies exposed to CAPLYTA during the third trimester. Talk to your healthcare provider if you breastfeed or are planning to breastfeed as CAPLYTA passes into breast milk. Tell your healthcare provider about all the medicines you're taking. CAPLYTA may affect the way other medicines work, and other medicines may affect how CAPLYTA works, causing possible serious side effects. Do not start or stop any medicines while taking CAPLYTA without talking to your healthcare provider. You are encouraged to report negative side effects of prescription drugs. Contact Intra‑Cellular Therapies, Inc. at 1‑888‑611‑4824 or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

CAPLYTA is available in 10.5 mg, 21 mg, and 42 mg capsules.

(DESCRIPTION)

Previous on screen text disappears and the screen becomes blue. The CAPLYTA logo is in the middle of the screen. There is legal language in the bottom left corner and the ITCI logo is in the bottom right corner.

[CAPLYTA logo]

[ITCI logo]